Immunovant To Release Initial IMVT-1402 Phase 1 Results Via Conference Call And Webcast On September 26, 2023
Portfolio Pulse from Benzinga Newsdesk
Immunovant is set to release initial results from the Phase 1 trial of IMVT-1402 via a conference call and webcast on September 26, 2023.
September 26, 2023 | 6:41 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Immunovant's stock may be impacted by the upcoming announcement of the Phase 1 results of IMVT-1402.
The announcement of clinical trial results often has a significant impact on a biotech company's stock. The direction of the impact will depend on whether the results meet, exceed, or fall short of expectations.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100